EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
CAR-T
EGFRvIII
Glioblastoma multiform
PD-1
PD-L1
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
29
06
2019
accepted:
01
10
2019
pubmed:
29
1
2020
medline:
13
7
2021
entrez:
29
1
2020
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is the most malignant form of the brain tumors. EGFR variant III (EGFRvIII) is expressed in about 30% of GBM specimens, but not expressed in normal brain tissues. Therefore, EGFRvIII protein offers an ideal CAR-T therapeutic target for EGFRvIII-positive GBM patients. PD-L1 is expressed in a variety of cancer cells, including GBM. Tumor-associated PD-L1 can bind to PD-1 on T cells and promote apoptosis of T cells, thus suppressing the anti-cancer immune response. In our current studies, PD-1
Identifiants
pubmed: 31989402
doi: 10.1007/s12253-019-00759-1
pii: 10.1007/s12253-019-00759-1
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
epidermal growth factor receptor VIII
0
Interferon-gamma
82115-62-6
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2135-2141Subventions
Organisme : National Natural Science Foundation of China
ID : 81772691 and 81370062
Références
Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2(9): 494-503; quiz 1 p following 516
Oike T, Suzuki Y, Sugawara K, Shirai K, Noda SE, Tamaki T, Nagaishi M, Yokoo H, Nakazato Y, Nakano T (2013) Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One 8(11):e78943
doi: 10.1371/journal.pone.0078943
Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31(32):4085–4091
doi: 10.1200/JCO.2013.49.6968
Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James CD (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9(8):2313–2320
pubmed: 8036013
Padfield E, Ellis HP, Kurian KM (2015) Current therapeutic advances targeting EGFR and EGFRvIII in Glioblastoma. Front Oncol 5:5
doi: 10.3389/fonc.2015.00005
Thorne AH, Zanca C, Furnari F (2016) Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro-Oncology 18(7):914–918
doi: 10.1093/neuonc/nov319
Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD Jr, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV (2015) Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 7(275):275ra22
doi: 10.1126/scitranslmed.aaa4963
Krenciute G, Krebs S, Torres D, Wu MF, Liu H, Dotti G, Li XN, Lesniak MS, Balyasnikova IV, Gottschalk S (2016) Characterization and functional analysis of scFv-based chimeric antigen receptors to redirect T cells to IL13Ralpha2-positive Glioma. Mol Ther 24(2):354–363
doi: 10.1038/mt.2015.199
O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 9(399):eaaa0984
Nishikori M, Takaori-Kondo A (2017) PD-1 blockade therapy in lymphoid malignancies. Rinsho Ketsueki 58(10):2043–2049
pubmed: 28978847
Lipson EJ, Lilo MT, Ogurtsova A, Esandrio J, Xu H, Brothers P, Schollenberger M, Sharfman WH, Taube JM (2017) Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer 5:23
doi: 10.1186/s40425-017-0228-3
Serganova I, Moroz E, Cohen I, Moroz M, Mane M, Zurita J, Shenker L, Ponomarev V, Blasberg R (2017) Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1/PD-L1 blockade. Mol Ther Oncolytics 4:41–54
doi: 10.1016/j.omto.2016.11.005
Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA (2015) Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23(12):2341–2348
doi: 10.1016/j.str.2015.09.010
Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ (2017) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 66(5):794–801
doi: 10.1136/gutjnl-2015-310839
Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U (2017) A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. PLoS One 12(10):e0186106
doi: 10.1371/journal.pone.0186106
Kim HM, Lee J, Koo JS (2017) Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer 17(1):690
doi: 10.1186/s12885-017-3670-1
Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB (2016) PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology 18(2):195–205
doi: 10.1093/neuonc/nov172
Sengupta S, Katz SC, Sengupta S, Sampath P (2018) Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells. Cancer Lett 433:131–139
doi: 10.1016/j.canlet.2018.06.035
Li Y, Qiu W, Zhang L, Fung J, Lin F (2016) Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage. Biomaterials 102:209–219
doi: 10.1016/j.biomaterials.2016.05.055
Watkins MP, Bartlett NL (2018) CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. Expert Opin Investig Drugs 27(7):601–611
doi: 10.1080/13543784.2018.1492549
Young PA, Yamada RE, Trinh KR, Vasuthasawat A, De Oliveira S, Yamada DH, Morrison SL, Timmerman JM (2018) Activity of anti-CD19 chimeric antigen receptor T cells against B cell lymphoma is enhanced by antibody-targeted interferon-alpha. J Interf Cytokine Res 38(6):239–254
doi: 10.1089/jir.2018.0030
Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296
doi: 10.1146/annurev.immunol.25.022106.141609
Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11(4):1462–1466
doi: 10.1158/1078-0432.CCR-04-1737
Sahin A, Sanchez C, Bullain S, Waterman P, Weissleder R, Carter BS (2018) Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLoS One 13(7):e0199414
doi: 10.1371/journal.pone.0199414
Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE 2nd, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH (2014) EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 9(4):e94281
doi: 10.1371/journal.pone.0094281
Thoma C (2016) Prostate cancer: PD-L1 expression is common and indicates poor prognosis. Nat Rev Urol 13(1):5
doi: 10.1038/nrurol.2015.287